The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed

The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed

Abstract Clofarabine is an active antileukemic drug for subgroups of patients with acute myeloid leukemia (AML). Multi‐state models can provide additional insights to supplement the original intention‐to‐treat analysis of randomized controlled trials (RCT). We re‐analyzed the HOVON102/SAKK30/09 phas...

Full description

Bibliographic Details
Main Authors: Katerina Bakunina, Hein Putter, Jurjen Versluis, Eva A. S. Koster, Bronno van derHolt, Markus G. Manz, Dimitri A. Breems, Bjorn T. Gjertsen, Jacqueline Cloos, Peter J. M. Valk, Jakob Passweg, Thomas Pabst, Gert J. Ossenkoppele, Bob Löwenberg, Jan J. Cornelissen, Liesbeth C. deWreede
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:Cancer Medicine
Subjects:
AML
clofarabine
current leukemia‐free survival
HSCT
multi‐state model
RCT
Online Access:https://doi.org/10.1002/cam4.4392

Internet

https://doi.org/10.1002/cam4.4392

Similar Items